分组1 - RE/MAX reported quarterly earnings of $0.3 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, with an earnings surprise of +7.14% [1] - The company posted revenues of $71.14 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.15%, and a decrease from year-ago revenues of $72.47 million [2] - Over the last four quarters, RE/MAX has surpassed consensus EPS estimates four times but has only topped consensus revenue estimates once [2] 分组2 - The stock has underperformed, losing about 10% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is $0.20 on revenues of $76.55 million, and for the current fiscal year, it is $1.26 on revenues of $296.19 million [7] - The Zacks Industry Rank for Real Estate - Operations is in the bottom 39% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

分组1 - Onto Innovation reported quarterly earnings of $1.26 per share, missing the Zacks Consensus Estimate of $1.28 per share, and down from $1.51 per share a year ago, representing an earnings surprise of -1.37% [1] - The company posted revenues of $266.87 million for the quarter, surpassing the Zacks Consensus Estimate by 0.10%, and up from $263.94 million year-over-year, having topped consensus revenue estimates three times over the last four quarters [2] - The stock has gained approximately 39.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Onto Innovation is crucial for investors, with current consensus EPS estimates at $1.29 for the coming quarter and $6.06 for the current fiscal year, alongside expected revenues of $271.09 million and $1.18 billion respectively [7] - The Zacks Industry Rank indicates that the Nanotechnology sector is currently in the top 3% of over 250 Zacks industries, suggesting a favorable environment for Onto Innovation's performance [8] - The company holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6]

分组1 - Travere Therapeutics reported quarterly earnings of $0.03 per share, aligning with the Zacks Consensus Estimate, compared to a loss of $0.73 per share a year ago, representing an earnings surprise of +16.73% [1] - The company posted revenues of $129.69 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 8.97%, and this is an increase from year-ago revenues of $74.79 million [2] - Travere has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed, losing about 27.1% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.07 on $135 million in revenues, and for the current fiscal year, it is $0.62 on $673.01 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

分组1 - Integer reported quarterly earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.7 per share, and up from $1.43 per share a year ago, representing an earnings surprise of +3.62% [1] - The company posted revenues of $472.06 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.04%, and an increase from $449.5 million year-over-year [2] - Integer has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] 分组2 - The stock has gained approximately 10.3% since the beginning of the year, compared to the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is $1.35 on revenues of $426.48 million, and for the current fiscal year, it is $6.32 on revenues of $1.84 billion [7] - The Medical - Instruments industry, to which Integer belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Talkspace, Inc. reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, and showing an increase from $0.01 per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $63 million for the quarter ended December 2025, which missed the Zacks Consensus Estimate by 0.16%, compared to revenues of $48.72 million in the same quarter last year [2] - Talkspace shares have increased by approximately 8.3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $67.3 million, and for the current fiscal year, it is $0.13 on revenues of $286 million [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 46% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8] - The estimate revisions trend for Talkspace was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

分组1 - Bausch Health reported quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.21 per share, and showing a decrease from $1.15 per share a year ago, resulting in an earnings surprise of -10.50% [1] - The company posted revenues of $2.8 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.38%, and an increase from $2.56 billion year-over-year [2] - Bausch has surpassed consensus revenue estimates three times over the last four quarters, while it has only surpassed consensus EPS estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 13.8% since the beginning of the year, compared to the S&P 500's zero return [3] - The current consensus EPS estimate for the coming quarter is $0.82 on revenues of $2.43 billion, and for the current fiscal year, it is $4.07 on revenues of $10.49 billion [7] - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the bottom 20% of the Zacks Industry Rank, indicating potential challenges for stock performance [8]

Core Viewpoint - Wyndham Hotels reported quarterly earnings of $0.93 per share, exceeding the Zacks Consensus Estimate of $0.89 per share, but down from $1.04 per share a year ago, indicating an earnings surprise of +4.07% [1] Financial Performance - The company posted revenues of $334 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 1.16%, and down from $341 million year-over-year [2] - Over the last four quarters, Wyndham has surpassed consensus EPS estimates four times but has topped consensus revenue estimates only once [2] Stock Performance - Wyndham shares have increased approximately 6.3% since the beginning of the year, contrasting with the S&P 500's zero return [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.90 for the coming quarter and $4.89 for the current fiscal year, with revenues expected to be $325.9 million and $1.51 billion respectively [7] - The Zacks Rank for Wyndham is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Hotels and Motels industry is currently in the bottom 45% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8]

分组1 - Community Health Systems (CYH) reported break-even quarterly earnings per share, surprising analysts who expected a loss of $0.32, and this is an improvement from a loss of $0.42 per share a year ago, indicating a +100.00% earnings surprise [1] - The company posted revenues of $3.11 billion for the quarter ended December 2025, which missed the Zacks Consensus Estimate by 1.18% and is a decrease from year-ago revenues of $3.27 billion [2] - Community Health Systems shares have increased by about 10.3% since the beginning of the year, outperforming the S&P 500, which has shown a zero return [3] 分组2 - The earnings outlook for Community Health Systems is mixed, with the current consensus EPS estimate for the coming quarter at -$0.19 on revenues of $3.16 billion, and -$0.51 on revenues of $12.73 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Hospital sector is currently in the bottom 28% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] - Universal Health Services (UHS), a competitor in the same industry, is expected to report quarterly earnings of $5.91 per share, reflecting a year-over-year change of +20.1%, with revenues anticipated to be $4.48 billion, up 9% from the previous year [9][10]

分组1 - Nextdoor Holdings, Inc. reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.03, representing an earnings surprise of +60.00% [1] - The company posted revenues of $69.48 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.13% and showing an increase from $65.23 million year-over-year [2] - Nextdoor has consistently surpassed consensus EPS estimates over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has underperformed the market, losing about 21.4% since the beginning of the year, while the S&P 500 has returned zero [3] - The current consensus EPS estimate for the coming quarter is -$0.05 on revenues of $59.59 million, and for the current fiscal year, it is -$0.15 on revenues of $275.03 million [7] - The Zacks Industry Rank for Internet - Software is in the bottom 48% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8]

分组1 - DoorDash reported quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.58 per share, but showing an increase from $0.33 per share a year ago, resulting in an earnings surprise of -17.24% [1] - The company posted revenues of $3.96 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 0.37%, and an increase from $2.87 billion year-over-year [2] - Over the last four quarters, DoorDash has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] 分组2 - DoorDash shares have declined approximately 28.3% since the beginning of the year, contrasting with the S&P 500's zero return [3] - The current consensus EPS estimate for the upcoming quarter is $0.63 on revenues of $4.12 billion, and for the current fiscal year, it is $3.14 on revenues of $17.82 billion [7] - The Zacks Industry Rank indicates that the Internet - Services sector is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]